Clinical Trial Update: Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates nivolumab plus ipilimumab for anti-PD1-resistant dMMR/MSI metastatic colorectal cancer. The study is currently recruiting und…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING